CIC
NVO

Chase Investment Counsel’s Novo Nordisk NVO Stock Holding History

Chase Investment Counsel’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,337
Closed -$754K – 144
2024
Q3 		$754K Buy
+6,337
New +$845K 0.25% 78

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Chase Investment Counsel's NVO Position: Q4 2024 in Review

Chase Investment Counsel sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 6,337 shares — an estimated $754K sold.

Chase Investment Counsel first reported a position in NVO in Q3 2024 and held it in 1 quarter. The position peaked at $754K in Q3 2024. 1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

  • Chase Investment Counsel reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
  • Chase Investment Counsel sold 6,337 Novo Nordisk shares in Q4 2024, an estimated $754K.
  • Chase Investment Counsel first reported a position in Novo Nordisk in Q3 2024 and held it in 1 quarter.
  • Chase Investment Counsel's Novo Nordisk position peaked at $754K in Q3 2024.
  • 1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on Chase Investment Counsel's 13F filing for Q4 2024, filed 5 Feb 2025.